General information on Anti-CoV-RBD (B5) antibody
The anti-CoV-RBD (B5) antibody targets the RBD – receptor-binding domain of the new pandemic strain of coronavirus, SARS-CoV-2. Initially detected in December 2019, the new strain continues to spread unattained causing unimaginable losses. Antibodies have been identified as potential game-changers in the development of life-saving therapies for the COVID-19 disease. Moreover, due to their shorter clinical development times in comparison to vaccines, antibodies can also be used to confer temporary immunity to risk groups such as health care workers, elderly, and immunodeficient individuals.
This specific antibody is a fully human IgG molecule with potential SARS-CoV-2 neutralizing activity, confirmed in competition assays using recombinant forms of the RBD and the ACE2 receptor protein (SARS-CoV-2 Surrogate Virus Neutralization Test, sVNT). Its neutralizing activity can be used to reinforce our knowledge regarding the infection mechanisms of SARS-CoV-2, to assess the potential development of spontaneous escape mutants which would result in lower therapeutic efficiencies, and to detect the presence of SARS-CoV-2 in multiple samples.
The fully human antibody’s specificity and binding affinity have been further tested and validated in ELISA plates (enzyme-linked immunosorbent assay) against the recombinant form of RBD. Additionally, the ease of expression and stability was further confirmed by producing milligram amounts of the recombinant antibody (rAb) in the transient CHO-based mammalian system, XtenCHO™.
There are no reviews yet.